Primary Vitreoretinal Lymphoma: Current Diagnostic Laboratory Tests and New Emerging Molecular Tools.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
24 09 2022
Historique:
received: 27 08 2022
revised: 16 09 2022
accepted: 19 09 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 29 10 2022
Statut: epublish

Résumé

Primary vitreoretinal lymphoma (PVRL), a rare aggressive malignancy primarily involving the retina and/or the vitreous, is a major diagnostic challenge for clinicians (who commonly misdiagnose it as chronic uveitis) as well as for pathologists (for biological and technical reasons). Delays in diagnosis and treatment are responsible for visual impairments and life-threatening consequences, usually related to central nervous system involvement. The identification of lymphoma cells in vitreous fluid, obtained by vitrectomy, is required for diagnosis. Of note, the scarcity of neoplastic cells in small volumes of vitreous sample, and the fragility of lymphoma cells with degenerative changes caused by previous steroid use for presumed uveitis makes diagnosis based on cytology plus immunophenotyping difficult. Interleukin levels, immunoglobulin heavy chain or T-cell receptor gene rearrangements, and MYD88 mutation are applied in combination with cytology to support diagnosis. We aim to describe the current laboratory technologies for PVRL diagnosis, focusing on the main issues that these methods have. In addition, new emerging diagnostic strategies, such as next-generation sequencing analysis, are discussed. The genetic profile of PVRL remains largely unexplored. Better knowledge of genetic alterations is critical for precision medicine interventions with target-based treatments of this lymphoma for which no standardised treatment protocol currently exists.

Identifiants

pubmed: 36290820
pii: curroncol29100543
doi: 10.3390/curroncol29100543
pmc: PMC9600627
doi:

Substances chimiques

Myeloid Differentiation Factor 88 0
Immunoglobulin Heavy Chains 0
Steroids 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

6908-6921

Références

Ocul Immunol Inflamm. 2009 Sep-Oct;17(5):299-306
pubmed: 19831557
Asia Pac J Ophthalmol (Phila). 2017 May-Jun;6(3):283-289
pubmed: 28558176
Blood. 2015 Jul 2;126(1):76-9
pubmed: 25900979
Retina. 2016 Mar;36(3):624-8
pubmed: 26900675
J Clin Med. 2020 Jun 12;9(6):
pubmed: 32545709
JAMA Ophthalmol. 2015 Feb;133(2):191-7
pubmed: 25412269
Blood Adv. 2022 Mar 8;6(5):1598-1607
pubmed: 34448823
Cancers (Basel). 2022 Jan 25;14(3):
pubmed: 35158867
Blood. 2017 Jun 8;129(23):3130-3133
pubmed: 28389463
Blood. 2006 Jan 1;107(1):190-6
pubmed: 16150948
Eur J Ophthalmol. 2014 Nov-Dec;24(6):911-7
pubmed: 24846625
Acta Neuropathol. 2011 Dec;122(6):791-2
pubmed: 22020631
Indian J Ophthalmol. 2016 May;64(5):369-75
pubmed: 27380976
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Invest Ophthalmol Vis Sci. 1990 May;31(5):917-20
pubmed: 2335453
Cancers (Basel). 2021 Aug 04;13(16):
pubmed: 34439078
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Curr Opin Neurol. 2019 Dec;32(6):886-894
pubmed: 31592789
Blood. 2011 Jan 27;117(4):1291-300
pubmed: 21088137
Ocul Immunol Inflamm. 2021 Aug 11;:1-9
pubmed: 34379571
Leukemia. 2008 Feb;22(2):400-5
pubmed: 17989719
Br J Haematol. 2016 Jun;173(5):680-92
pubmed: 27133587
Eye (Lond). 2013 Feb;27(2):153-62
pubmed: 23196650
Asia Pac J Ophthalmol (Phila). 2021 Jan 19;10(1):93-98
pubmed: 33481398
Eur J Haematol. 2019 Feb;102(2):191-196
pubmed: 30390359
Haematologica. 2019 Dec;104(12):2337-2348
pubmed: 31699794
Nature. 2011 Feb 3;470(7332):115-9
pubmed: 21179087
Nat Med. 2018 Aug;24(8):1290-1291
pubmed: 29955182
Oncotarget. 2017 Jan 31;8(5):7989-7998
pubmed: 28002793
Front Mol Biosci. 2021 Jan 11;7:611017
pubmed: 33505989
Ophthalmology. 2016 Jul;123(7):1626-8
pubmed: 26948307
Blood. 2019 Aug 22;134(8):709-712
pubmed: 31292111
Indian J Ophthalmol. 2020 Oct;68(10):2160-2165
pubmed: 32971631
Am J Ophthalmol. 2014 Mar;157(3):728-34
pubmed: 24345320
Hematol Oncol. 2020 Dec;38(5):640-647
pubmed: 32510610
Prog Retin Eye Res. 2022 Sep;90:101053
pubmed: 35210172
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1890-3
pubmed: 1371884
Int J Mol Sci. 2021 Sep 16;22(18):
pubmed: 34576156
Int J Mol Sci. 2011;12(9):5684-97
pubmed: 22016619
F1000Prime Rep. 2014 Nov 04;6:97
pubmed: 25580251
Retina. 2021 Dec 1;41(12):2596-2604
pubmed: 34173362
Ocul Immunol Inflamm. 2021 Apr 03;29(3):507-520
pubmed: 34009095
Blood. 2015 Jul 2;126(1):4-5
pubmed: 26138536
Arch Neurol. 2010 Mar;67(3):291-7
pubmed: 20212226
Acta Ophthalmol. 2020 Sep;98(6):e668-e673
pubmed: 31994839
Oncologist. 2011;16(11):1589-99
pubmed: 22045784
Int J Retina Vitreous. 2018 May 7;4:18
pubmed: 29760948
Am J Ophthalmol. 1997 Sep;124(3):362-72
pubmed: 9439362
Haematologica. 2020 Jun 05;105(9):e458-460
pubmed: 33054063
Blood. 2021 Oct 28;138(17):1519-1534
pubmed: 34036310
Ophthalmology. 2013 May;120(5):991-6
pubmed: 23380473
Front Oncol. 2022 Jul 19;12:932674
pubmed: 35928872

Auteurs

Beatrice Melli (B)

Molecular Pathology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Department of Obstetrics and Gynaecology, Fertility Center, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41124 Modena, Italy.

Pietro Gentile (P)

Department of Surgical Sciences, Eye Clinic, University of Cagliari, 09124 Cagliari, Italy.

Davide Nicoli (D)

Molecular Pathology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Enrico Farnetti (E)

Molecular Pathology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Stefania Croci (S)

Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Fabrizio Gozzi (F)

Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Elena Bolletta (E)

Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Luca De Simone (L)

Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Francesca Sanguedolce (F)

Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.

Andrea Palicelli (A)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Maurizio Zizzo (M)

Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Stefano Ricci (S)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Fiorella Ilariucci (F)

Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Cristiana Rossi (C)

Pathology Unit, Azienda Unità Sanitaria Locale ASL5 La Spezia, 19124 La Spezia, Italy.

Alberto Cavazza (A)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Stefano Ascani (S)

Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy.

Luca Cimino (L)

Ocular Immunology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy.

Magda Zanelli (M)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH